

The Changing Landscape of Substance Use Disorders

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within topics and years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

2019

- Lowe DJE, Sasiadek JD, Coles AS, et al: Cannabis and mental illness: a review. *Eur Arch Psychiatry Clin Neurosci* 2019; 269:107–120
- Nielsen S, Gowing L, Sabioni P, et al: Pharmacotherapies for cannabis dependence. *Cochrane Database Syst Rev* 2019; 1: CD008940
- Sullivan MA, Bisaga A, Pavlicova M, et al: A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. *Am J Psychiatry* 2019; 176: 129–137
- Uhl GR, Koob GF, Cable J: The neurobiology of addiction. *Ann N Y Acad Sci* 2019
- Vermeulen J, Schirmbeck F, Blankers M, et al: Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study. *Lancet Psychiatry* 2019; 6:25–34

2018

- Brezing CA, Levin FR: The current state of pharmacological treatments for cannabis use disorder and withdrawal. *Neuropsychopharmacology* 2018; 43:173–194
- Crescenzo F, Ciabattini M, Cipriani A et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. *PLoS Med.* 2018 Dec 26;15(12):e1002715.
- Deng H, Verrico CD, Kosten TR, et al: Psychosis and synthetic cannabinoids. *Psychiatry Res* 2018; 268:400–412
- Farahzadi MH, Moazen-Zadeh E, Razaghi E, et al: Riluzole for treatment of men with methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. *J Psychopharmacol* 2018; 33:305–315
- Hurt RT, Ebbert JO, Croghan IT, et al: Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: a randomized controlled trial. *Drug Alcohol Depend* 2018; 184:12–17
- Larochelle MR, Bernson D, Land T, et al: Medication for opioid use disorder after nonfatal opioid overdose and

association with mortality: a cohort study. *Ann Intern Med* 2018; 169:137–145

- Lee JD, Nunes EV Jr, Novo P, et al: Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet* 2018; 391: 309–318

Reus VI, Fochtmann LJ, Bukstein O, et al: The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. *Am J Psychiatry* 2018; 175:86–90

Sabioni P, Le Foll B: Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. *F1000 Res* 2018; 7:173

Scott JC, Slomiak ST, Jones JD, et al: Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. *JAMA Psychiatry* 2018; 75:585–595

Volkow ND, Jones EB, Einstein EB, et al: Prevention and treatment of opioid misuse and addiction: a review. *JAMA Psychiatry* 2019; 76:208–216

Zehra A, Burns J, Liu CK, et al: Cannabis addiction and the brain: a review. *J Neuroimmune Pharmacol* 2018; 13: 438–452

2017

- Bahorik AL, Leibowitz A, Sterling SA, et al: Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. *J Affect Disord* 2017; 213:168–171
- Carroll KM, Kiluk BD: Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again. *Psychol Addict Behav* 2017; 31: 847–861
- Carroll KM, Weiss RD: The role of behavioral interventions in buprenorphine maintenance treatment: a review. *Am J Psychiatry* 2017; 174:738–747**
- Hassan AN, Howe AS, Samokhvalov AV, et al: Management of mood and anxiety disorders in patients receiving opioid agonist therapy: review and meta-analysis. *Am J Addict* 2017; 26:551–563

- Hser YI, Huang D, Saxon AJ, et al: Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+naloxone and methadone. *J Addict Med* 2017; 11:63–69
- Klaman SL, Isaacs K, Leopold A, et al: Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. *J Addict Med* 2017; 11:178–190
- Sordo L, Barrio G, Bravo MJ, et al: Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ* 2017; 357:j1550
- Webster LR: Risk factors for opioid-use disorder and overdose. *Anesth Analg* 2017; 125:1741–1748
- FURTHER READING**
- Blanco C, Rafful C, Wall MM, et al: Towards a comprehensive developmental model of cannabis use disorders. *Addiction* 2014; 109:284–294
- Gates PJ, Sabioni P, Copeland J, et al: Psychosocial interventions for cannabis use disorder. *Cochrane Database Syst Rev* 2016; (5):CD005336
- Humphreys K, Blodgett JC, Wagner TH: Estimating the efficacy of Alcoholics Anonymous without self-selection bias: an instrumental variables re-analysis of randomized clinical trials. *Alcohol Clin Exp Res* 2014; 38: 2688–2694
- Tang YY, Tang R, Posner MI: Mindfulness meditation improves emotion regulation and reduces drug abuse. *Drug Alcohol Depend* 2016; 163(Suppl 1):S13–S18 [Review]
- Yuodelis-Flores C, Ries RK: Addiction and suicide: a review. *Am J Addict* 2015; 24:98–104**
- Zulauf CA, Sprich SE, Safren SA, et al: The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. *Curr Psychiatry Rep* 2014; 16: 436